Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
antibodies, with Immunome receiving target exclusivity and Infinimmune handling discovery and optimization responsibilities. This alliance leverages Infinimmune's GLIMPSE and Anthrobody platforms, potentially expanding Immunome's therapeutic pipeline and their future development opportunities. We'll explore how target exclusivity from this collaboration may influence Immunome's investment narrative and outlook. Uncover the next big thing with financially sound penny stocks that balance risk and reward What Is Immunome's Investment Narrative? For investors interested in Immunome, the main story has long been about its high-risk, high-reward profile: rapid revenue growth forecasts, continued operating losses, and a volatile stock price that's underperformed its peers and the broader market over the past year. The new research collaboration with Infinimmune is meaningful because it has the potential to broaden Immunome's therapeutic pipeline through exclusive access to novel an
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Immunome (NASDAQ:IMNM) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $36.00 price target on the stock.MarketBeat
- Immunome to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Immunome to Present at Upcoming Investor ConferencesBusiness Wire
- Immunome (NASDAQ:IMNM) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMNM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 11/7/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- IMNM's page on the SEC website